


Healthcare News Roundup: Biopharmaceuticals
HSMN NewsFeed - 12 Dec 2022
Amgen to Host Webcast Investor Call Following Announced Acquisition of Horizon Therapeutics
Amgen to Host Webcast Investor Call Following Announced Acquisition of Horizon Therapeutics
HSMN NewsFeed - 8 Dec 2022
Dantari Debuts with $47 Million Series A to Advance Best-in-Class Targeted Medicines for Solid Tumors
Dantari Debuts with $47 Million Series A to Advance Best-in-Class Targeted Medicines for Solid Tumors
HSMN NewsFeed - 30 Nov 2022
Aeglea BioTherapeutics Appoints Jeffrey M. Goldberg as Chief Executive Officer
Aeglea BioTherapeutics Appoints Jeffrey M. Goldberg as Chief Executive Officer
HSMN NewsFeed - 18 Nov 2022
Synaptogenix Announces $15 Million Private Placement with Existing Investors
Synaptogenix Announces $15 Million Private Placement with Existing Investors
HSMN NewsFeed - 10 Nov 2022
Lipidio Pharmaceuticals Announces Close of Series A Extension Financing, Bringing Total Round to Over $20M
Lipidio Pharmaceuticals Announces Close of Series A Extension Financing, Bringing Total Round to Over $20M
HSMN NewsFeed - 9 Nov 2022
Odyssey Therapeutics Expands Management Team with Key Appointments in Research Development and Strategy
Odyssey Therapeutics Expands Management Team with Key Appointments in Research Development and Strategy
HSMN NewsFeed - 25 Oct 2022
Actinium Bolsters its Senior Leadership Team Ahead of Upcoming Clinical Data for Iomab-B
Actinium Bolsters its Senior Leadership Team Ahead of Upcoming Clinical Data for Iomab-B
HSMN NewsFeed - 21 Oct 2022
Regeneron Receives Six Months of U.S. Pediatric Exclusivity for EYLEA(R) (aflibercept) Injection
Regeneron Receives Six Months of U.S. Pediatric Exclusivity for EYLEA(R) (aflibercept) Injection
